Fluorocarbon emulsions with reduced pulmonary gas-trapping properties
AssigneeAlliance Pharmaceutical Corp.
InventorsJeffry G. Weers, Ernest G. Schutt, Timothy J. Pelura, Peter E. Keipert
Life of this patent
Estimating the term…
Abstract
A fluorocarbon emulsion which exhibits reduced pulmonary gas-trapping properties in species-sensitive laboratory animals is disclosed. Additionally, the fluorocarbon component(s) exhibit short organ retention time(s). The emulsion includes an aqueous phase, an emulsifier, and a fluorocarbon (or fluorocarbon composition), having a vapor pressure of less than about 8 torr to reduce pulmonary gas-trapping, and having an organ retention half life of less than about 6 weeks and more preferably less than about 3 to 4 weeks.
Claims15
A fluorocarbon emulsion exhibiting reduced pulmonary gas-trapping properties, comprising:
- an aqueous phase;
- an emulsifying agent;
- and
- a liquid fluorocarbon phase comprising a mixture of at least two fluorocarbons in a weight ratio of from about 20:1 to about 1:20 wherein at least one fluorocarbon has a covalently attached lipophilic moiety consisting of Br, Cl or I saturated or unsaturated hydrocarbon chain of 2 or 3 carbon atoms, said mixture having a vapor pressure of less than about 20 Torr at 37.degree. C., and having an organ half-life of less than about 6 weeks.
A fluorocarbon emulsion exhibiting reduced pulmonary gas-trapping properties, comprising:
- an aqueous phase;
- an emulsifier;
- and
- a fluorocarbon phase including at least 10% weight by volume of F-decyl bromide.
In a method of preparing a fluorocarbon emulsion for intravenous administration to a patient, by forming an emulsion of an aqueous phase, an emulsifier, and a first fluorocarbon in a fluorocarbon phase wherein the vapor pressure of the fluorocarbon phase is greater than about 8 Torr at 37.degree. C., the improvement comprising:
- reducing the pulmonary gas trapping effect of the emulsion upon intravenous administration by providing in combination with the first fluorocarbon in the fluorocarbon phase an effective amount of a second fluorocarbon comprising a covalently attached lipophilic moiety selected from the group consisting of Br, Cl or I, wherein the addition of the second fluorocarbon reduces the vapor pressure of the fluorocarbon phase at 37.degree. C. to less than about 8 Torr and wherein the fluorocarbon phase has a melting point less than about 37.degree. C. and an organ retention half-life less than about 4 weeks.
In a method for administering a fluorocarbon emulsion to a mammal, wherein the emulsion comprises an aqueous phase, an emulsifier, and a first fluorocarbon in a fluorocarbon phase wherein the vapor pressure of the fluorocarbon phase is greater than about 8 Torr at 37.degree. C., the improvement comprising:
- reducing the pulmonary gas trapping effect of the emulsion upon intravenous administration by providing in combination with the first fluorocarbon in the fluorocarbon phase an effective amount of a second fluorocarbon comprising a covalently attached lipophilic moiety selected from the group consisting of Br, Cl or I, wherein the addition of the second fluorocarbon reduces the vapor pressure of the fluorocarbon phase at 37.degree. C. to less than about 8 Torr and wherein the fluorocarbon phase has a melting point less than about 37.degree. C. and an organ retention half-life less than about 4 weeks.
Dependencies are inferred from the claim text.